Novavax shares are trading higher after the company announced that the Novavax COVID-19 Vaccine, NVX-CoV2705, received Emergency Use Authorization from the FDA for active immunization to prevent COVID-19 in individuals aged 12 and older.
Portfolio Pulse from Benzinga Newsdesk
Novavax's COVID-19 vaccine, NVX-CoV2705, has received Emergency Use Authorization from the FDA for individuals aged 12 and older, leading to a rise in Novavax shares.
August 30, 2024 | 7:55 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Novavax's COVID-19 vaccine, NVX-CoV2705, has received Emergency Use Authorization from the FDA for individuals aged 12 and older, leading to a rise in Novavax shares.
The FDA's Emergency Use Authorization is a significant regulatory milestone that allows Novavax to distribute its COVID-19 vaccine to a broader age group. This development is likely to increase demand for the vaccine, positively impacting Novavax's revenue and stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100